Spotlight On... EHRs not yet ready for outcome-based drug pricing

Electronic health records have the potential to support outcome-based drug pricing, but are not yet capable of accurately tracking a drug's role in improving patient outcomes, such as reducing readmissions, Reuters reports. The article, which interviewed the CEOs of drug manufacturers Novartis and Roche, notes that the current pay-per-pill approach will eventually be unsustainable from a cost standpoint.

Other barriers to outcome-based drug pricing include the need for a large IT infrastructure to support it, medical privacy concerns and resistance from doctors who fear an increased administration burden and bureaucracy. Article

Suggested Articles

Roche, which already owned a 12.6% stake in Flatiron Health, has agreed to buy the health IT company for $1.9 billion.

Allscripts managed to acquire two EHR platforms for just $50 million by selling off a portion of McKesson's portfolio for as much as $235 million.

Artificial intelligence could help physicians predict a patient's risk of developing a deadly infection.